Lu et al. (133) reported that AD targets BIRC5 and FEN1, genes closely linked to immune modulation, producing substantial anticancer effects in HCC patients via the combined action of cantharidin, formononetin, and isofraxidin. Here, FEN1 is linked to hepatocellular carcinoma.